-
公开(公告)号：US20050080111A1
公开(公告)日：2005-04-14
申请号：US10899458
申请日：2004-07-24
申请人： Christopher Bayne , Alan Johnson , Shao-Po Lu , Raju Mohan , Michael Nyman , Edwin Schweiger , William Stevens , Haixia Wang , Yinong Xie
发明人： Christopher Bayne , Alan Johnson , Shao-Po Lu , Raju Mohan , Michael Nyman , Edwin Schweiger , William Stevens , Haixia Wang , Yinong Xie
IPC分类号： C07D213/85 , C07D401/04 , C07D401/06 , C07D401/12 , C07D405/04 , C07D405/06 , C07D405/12 , C07D409/04 , C07D413/06 , C07D417/04 , C07D417/06 , C07D417/12 , A61K31/4439 , C07D43/02
CPC分类号： C07D401/12 , C07D213/84 , C07D213/85 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/14 , C07D405/04 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/04 , C07D409/06 , C07D409/14 , C07D413/06 , C07D417/04 , C07D417/06 , C07D417/12
摘要： Compounds of the invention, such as compounds of formula (I): where n, m, A, B, R1, R2, R3, R4 and R5 are defined herein, are useful as modulators of the activity of liver X receptors. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
摘要翻译： 本发明化合物，例如式（I）化合物：其中n，m，A，B，R 1，R 2，R 3，R 4和R 5如本文所定义 ，可用作肝X受体活性的调节剂。 还公开了含有化合物的药物组合物和使用该化合物的方法。
-
公开(公告)号：US08569352B2
公开(公告)日：2013-10-29
申请号：US11993529
申请日：2006-06-26
申请人： Brett B. Busch , Brenton T. Flatt , Xiao-Hui Gu , Shao-Po Lu , Richard Martin , Raju Mohan , Michael Charles Nyman , Edwin Schweiger , William C. Stevens, Jr. , Tie-Lin Wang , Yinong Xie
发明人： Brett B. Busch , Brenton T. Flatt , Xiao-Hui Gu , Shao-Po Lu , Richard Martin , Raju Mohan , Michael Charles Nyman , Edwin Schweiger , William C. Stevens, Jr. , Tie-Lin Wang , Yinong Xie
IPC分类号： A61K31/4174 , C07D233/64
CPC分类号： C07D233/64 , C07D231/12 , C07D231/22 , C07D233/90 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/10 , C07D405/12 , C07D405/14 , C07D409/04 , C07D409/10 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/10 , C07D417/12 , C07D417/14 , C07D487/08
摘要： Compounds of the invention, such as compounds of Formulae IIa, IIb, IIc or IId, and pharmaceutically acceptable salts, isomers, and prodrugs thereof, are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3 and G are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
摘要翻译： 本发明的化合物，例如式IIa，IIb，IIc或IId的化合物及其药学上可接受的盐，异构体和前药可用作肝脏X受体活性的调节剂，其中R1，R2，R21，R3和 G在本文中定义。 还公开了含有化合物的药物组合物和使用该化合物的方法。
-
公开(公告)号：US20100331295A1
公开(公告)日：2010-12-30
申请号：US11993806
申请日：2006-06-26
申请人： Brett B Busch , Brenton T. Flatt , Xiao Hui Gu , Shao Po Lu , Richard Martin , Raju Mohan , Michael Charles Nyman , Edwin Schweiger , William C. Stevens, JR. , Tie Lin Wang , Yinong Xie
发明人： Brett B Busch , Brenton T. Flatt , Xiao Hui Gu , Shao Po Lu , Richard Martin , Raju Mohan , Michael Charles Nyman , Edwin Schweiger , William C. Stevens, JR. , Tie Lin Wang , Yinong Xie
IPC分类号： A61K31/4155 , C07D409/04 , C07D231/12 , C07D401/04 , C07D413/10 , C07D409/14 , C07D403/10 , A61K31/4439 , A61K31/454 , A61K31/5377 , A61K31/496 , A61P3/06 , A61P3/10 , A61P9/10 , A61P17/10 , A61P25/16 , A61P25/28 , A61P35/00 , A61P29/00 , A61P37/00 , A61P3/04
CPC分类号： C07D233/64 , C07D231/12 , C07D231/22 , C07D233/90 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/10 , C07D405/12 , C07D405/14 , C07D409/04 , C07D409/10 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/10 , C07D417/12 , C07D417/14 , C07D487/08
摘要： Compounds of the invention, such as compounds of Formulae Ia, Ib, Ic, or Id and pharmaceutically acceptable salts, isomers, and prodrugs thereof, which are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3, and G are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
摘要翻译： 本发明的化合物，例如式Ia，Ib，Ic或Id的化合物及其药学上可接受的盐，异构体和前药，其可用作肝脏X受体活性的调节剂，其中R1，R2，R21，R3 ，和G在本文中定义。 还公开了含有该化合物的药物组合物和使用该化合物的方法。
-
公开(公告)号：US08703805B2
公开(公告)日：2014-04-22
申请号：US11993806
申请日：2006-06-26
申请人： Brett B. Busch , Brenton T. Flatt , Xiao Hui Gu , Shao Po Lu , Richard Martin , Raju Mohan , Michael Charles Nyman , Edwin Schweiger , William C. Stevens, Jr. , Tie Lin Wang , Yinong Xie
发明人： Brett B. Busch , Brenton T. Flatt , Xiao Hui Gu , Shao Po Lu , Richard Martin , Raju Mohan , Michael Charles Nyman , Edwin Schweiger , William C. Stevens, Jr. , Tie Lin Wang , Yinong Xie
IPC分类号： A61K31/4155 , C07D231/12
CPC分类号： C07D233/64 , C07D231/12 , C07D231/22 , C07D233/90 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/10 , C07D405/12 , C07D405/14 , C07D409/04 , C07D409/10 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/10 , C07D417/12 , C07D417/14 , C07D487/08
摘要： Compounds of the invention, such as compounds of Formulae Ia, Ib, Ic, or Id and pharmaceutically acceptable salts, isomers, and prodrugs thereof, which are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3, and G are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
摘要翻译： 本发明的化合物，例如式Ia，Ib，Ic或Id的化合物及其药学上可接受的盐，异构体和前药，其可用作肝脏X受体活性的调节剂，其中R1，R2，R21，R3 ，和G在本文中定义。 还公开了含有化合物的药物组合物和使用该化合物的方法。
-
公开(公告)号：US20100069367A1
公开(公告)日：2010-03-18
申请号：US12517800
申请日：2007-12-07
申请人： Brant Clayton Boren , Brett B. Busch , Xiao-Hui Gu , Vasu Jammalamadaka , Shao Po Lu , Richard Martin , Raju Mohan , Edwin Schweiger , William C. Stevens , Tie-Lin Wang , Yinong Xie , Wei Xu
发明人： Brant Clayton Boren , Brett B. Busch , Xiao-Hui Gu , Vasu Jammalamadaka , Shao Po Lu , Richard Martin , Raju Mohan , Edwin Schweiger , William C. Stevens , Tie-Lin Wang , Yinong Xie , Wei Xu
IPC分类号： A61K31/551 , C07D231/12 , A61K31/415 , C07D233/54 , A61K31/4164 , C07D215/38 , A61K31/47 , C07D413/02 , A61K31/421 , C07D277/08 , A61K31/426 , C07D271/06 , A61K31/4245 , C07D403/02 , A61K31/505 , C07D401/02 , A61K31/4439 , A61K31/5377 , C07D401/14 , A61K31/496 , C07D243/08 , A61P9/00 , A61P25/00 , A61P35/00 , A61P29/00 , A61P3/00 , A61P37/00
CPC分类号： C07D233/90 , C07D231/10
摘要： Compounds of the invention are disclosed, such as compounds of formulae LX-LXIV, and pharmaceutically acceptable salts, isomers, or prodrugs thereof, which are useful as modulators of the activity of liver X receptors (LXR) and Farnesoid X receptors (FXR), where R00, R200, R400, R500, J11, J21, G1, G21, and Q are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
摘要翻译： 公开了本发明的化合物，例如式LX-LXIV的化合物及其药学上可接受的盐，异构体或前药，其可用作肝脏X受体（LXR）和法尼斯X受体（FXR）的活性的调节剂， 其中R00，R200，R400，R500，J11，J21，G1，G21和Q在本文中定义。 还公开了含有化合物的药物组合物和使用该化合物的方法。
-
公开(公告)号：US07998995B2
公开(公告)日：2011-08-16
申请号：US12517800
申请日：2007-12-07
申请人： Brant Clayton Boren , Brett B. Busch , Xiao-Hui Gu , Vasu Jammalamadaka , Shao Po Lu , Richard Martin , Raju Mohan , Edwin Schweiger , William C. Stevens , Tie-Lin Wang , Yinong Xie , Wei Xu
发明人： Brant Clayton Boren , Brett B. Busch , Xiao-Hui Gu , Vasu Jammalamadaka , Shao Po Lu , Richard Martin , Raju Mohan , Edwin Schweiger , William C. Stevens , Tie-Lin Wang , Yinong Xie , Wei Xu
IPC分类号： A61K31/4178 , A61K31/4164 , C07D233/56 , C07D233/58 , C07D233/66 , C07D233/64
CPC分类号： C07D233/90 , C07D231/10
摘要： Compounds of the invention are disclosed, such as compounds of formulae LX-LXIV, and pharmaceutically acceptable salts, isomers, or prodrugs thereof, which are useful as modulators of the activity of liver X receptors (LXR) and Farnesoid X receptors (FXR), where R00, R200, R400, R500, J11, J21, G1, G21, and Q are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
摘要翻译： 公开了本发明的化合物，例如式LX-LXIV的化合物及其药学上可接受的盐，异构体或前药，其可用作肝脏X受体（LXR）和法尼斯X受体（FXR）的活性的调节剂， 其中R00，R200，R400，R500，J11，J21，G1，G21和Q在本文中定义。 还公开了含有化合物的药物组合物和使用该化合物的方法。
-
公开(公告)号：US20100075964A1
公开(公告)日：2010-03-25
申请号：US11993529
申请日：2006-06-26
申请人： Brett B. Busch , Brenton T. Flatt , Xiao-Hui Gu , Shao-Po Lu , Richard Martin , Raju Mohan , Michael Charles Nyman , Edwin Schweiger , William C. Stevens, Jr. , Tie-Lin Wang , Yinong Xie
发明人： Brett B. Busch , Brenton T. Flatt , Xiao-Hui Gu , Shao-Po Lu , Richard Martin , Raju Mohan , Michael Charles Nyman , Edwin Schweiger , William C. Stevens, Jr. , Tie-Lin Wang , Yinong Xie
IPC分类号： A61K31/5377 , C07D233/54 , A61K31/4164 , C07D401/14 , A61K31/4439 , A61K31/496 , C07D413/14 , A61P3/06 , A61P9/00 , A61P25/00 , A61P35/00
CPC分类号： C07D233/64 , C07D231/12 , C07D231/22 , C07D233/90 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/10 , C07D405/12 , C07D405/14 , C07D409/04 , C07D409/10 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/10 , C07D417/12 , C07D417/14 , C07D487/08
摘要： Compounds of the invention, such as compounds of Formulae IIa, IIb, IIc or IId, and pharmaceutically acceptable salts, isomers, and prodrugs thereof, are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3 and G are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
摘要翻译： 本发明的化合物，例如式IIa，IIb，IIc或IId的化合物及其药学上可接受的盐，异构体和前药可用作肝脏X受体活性的调节剂，其中R1，R2，R21，R3和 G在本文中定义。 还公开了含有化合物的药物组合物和使用该化合物的方法。
-
公开(公告)号：US08163771B2
公开(公告)日：2012-04-24
申请号：US12381682
申请日：2009-03-13
申请人： Richard Martin , Brenton T. Flatt , Jackline Eve Dalgard , Venkataiah Bollu , Ping Huang , Raju Mohan , Edwin Schweiger , Tie-Lin Wang
发明人： Richard Martin , Brenton T. Flatt , Jackline Eve Dalgard , Venkataiah Bollu , Ping Huang , Raju Mohan , Edwin Schweiger , Tie-Lin Wang
IPC分类号： A10N43/42 , A61K31/44 , C07D451/00
CPC分类号： C07D451/04
摘要： A compound according to Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R11, L1 and X are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.
摘要翻译： 根据式I的化合物或其药学上可接受的盐，其中R 1，R 2，R 11，L 1和X如本说明书中所定义，其药物组合物及其使用方法。
-
公开(公告)号：US20090247515A1
公开(公告)日：2009-10-01
申请号：US12381682
申请日：2009-03-13
申请人： Richard Martin , Brenton T. Flatt , Jackline Eve Dalgard , Venkataiah Bollu , Ping Huang , Raju Mohan , Edwin Schweiger , Tie-Lin Wang
发明人： Richard Martin , Brenton T. Flatt , Jackline Eve Dalgard , Venkataiah Bollu , Ping Huang , Raju Mohan , Edwin Schweiger , Tie-Lin Wang
IPC分类号： A61K31/46 , C07D451/02 , A61K31/5377 , A61P3/00
CPC分类号： C07D451/04
摘要： A compound according to Formula A: or a pharmaceutically acceptable salt thereof, wherein R11, G1 and G2 are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.
摘要翻译： 根据式A的化合物或其药学上可接受的盐，其中R 11，G 1和G 2如本说明书中所定义，其药物组合物及其使用方法。
-
公开(公告)号：US20100105675A2
公开(公告)日：2010-04-29
申请号：US12381682
申请日：2009-03-13
申请人： Richard Martin , Brenton Flatt , Jackline Dalgard , Venkataiah Bollu , Ping Huang , Raju Mohan , Edwin Schweiger , Tie Lin Wang
发明人： Richard Martin , Brenton Flatt , Jackline Dalgard , Venkataiah Bollu , Ping Huang , Raju Mohan , Edwin Schweiger , Tie Lin Wang
IPC分类号： A61K31/46 , C07D451/02 , A61K31/5377 , A61P3/00
CPC分类号： C07D451/04
摘要： A compound according to Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R11, L1 and X are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.
摘要翻译： 根据式I的化合物或其药学上可接受的盐，其中R 1，R 2，R 11，L 1和X如本说明书中所定义，其药物组合物及其使用方法。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.07 秒)
